Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

ClinicalTrials.gov ID: NCT03285594

Public ClinicalTrials.gov record NCT03285594. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs)

Study identification

NCT ID
NCT03285594
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Lexicon Pharmaceuticals
Industry
Enrollment
571 participants

Conditions and interventions

Interventions

  • Sotagliflozin Drug
  • Insulin glargine (HOE901) Drug
  • Placebo Drug
  • Oral Antidiabetes Drugs (OADs) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 14, 2017
Primary completion
Sep 16, 2019
Completion
Sep 26, 2019
Last update posted
May 10, 2021

2017 – 2019

United States locations

U.S. sites
50
U.S. states
18
U.S. cities
45
Facility City State ZIP Site status
Investigational Site Number 8406028 Mesa Arizona 85213-5226
Investigational Site Number 8406013 Phoenix Arizona 85018
Investigational Site Number 8406020 Phoenix Arizona 85020
Investigational Site Number 8406006 Huntington Park California 90255
Investigational Site Number 8406053 Lincoln California 95648
Investigational Site Number 8406040 Los Angeles California 90057
Investigational Site Number 8406043 Coral Gables Florida 33134
Investigational Site Number 8406008 DeLand Florida 32720
Investigational Site Number 8406030 Maitland Florida 32751
Investigational Site Number 8406003 New Port Richey Florida 34652
Investigational Site Number 8406029 North Miami Beach Florida 33162
Investigational Site Number 8406052 Ocoee Florida 34761
Investigational Site Number 8406001 Port Charlotte Florida 33952
Investigational Site Number 8406022 St. Petersburg Florida 33700
Investigational Site Number 8406025 Tampa Florida 33634
Investigational Site Number 8406002 West Palm Beach Florida 33401-3430
Investigational Site Number 8406054 Chicago Illinois 60602
Investigational Site Number 8406027 Chicago Illinois 60604
Investigational Site Number 8406042 Evansville Indiana 47714
Investigational Site Number 8406044 New Orleans Louisiana 70119-6302
Investigational Site Number 8406051 New Orleans Louisiana 70124
Investigational Site Number 8406024 Rockville Maryland 20852
Investigational Site Number 8406016 Detroit Michigan 48202
Investigational Site Number 8406011 St Louis Missouri 63110
Investigational Site Number 8406010 Papillion Nebraska 68046-3136
Investigational Site Number 8406018 New York New York 10016-6023
Investigational Site Number 8406034 Asheville North Carolina 28803
Investigational Site Number 8406046 Chapel Hill North Carolina 27517
Investigational Site Number 8406026 Charlotte North Carolina 28209
Investigational Site Number 8406038 Greenville North Carolina 27834
Investigational Site Number 8406036 Hickory North Carolina 28601
Investigational Site Number 8406015 Wilmington North Carolina 28401-6638
Investigational Site Number 8406019 Winston-Salem North Carolina 27103
Investigational Site Number 8406031 Beachwood Ohio 44122
Investigational Site Number 8406023 Columbus Ohio 43201
Investigational Site Number 8406005 Dublin Ohio 43016
Investigational Site Number 8406004 Mentor Ohio 44060
Investigational Site Number 8406033 Oklahoma City Oklahoma 73111
Investigational Site Number 8406032 Moncks Corner South Carolina 29461-5017
Investigational Site Number 8406009 Chattanooga Tennessee 37421
Investigational Site Number 8406045 Seymour Tennessee 37865-5270
Investigational Site Number 8406047 Dallas Texas 75230
Investigational Site Number 8406017 Dallas Texas 75231
Investigational Site Number 8406048 Houston Texas 77079
Investigational Site Number 8406037 Houston Texas 77099
Investigational Site Number 8406039 McAllen Texas 78504
Investigational Site Number 8406050 San Antonio Texas 78229
Investigational Site Number 8406021 Shavano Park Texas 78231
Investigational Site Number 8406035 Salt Lake City Utah 84102-1553
Investigational Site Number 8406014 West Jordan Utah 84088-8865

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03285594, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 10, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03285594 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →